Incidence and Predictors of Complications Following Percutaneous Liver Biopsy: A Large Italian Multicentre Study
DOI:
10.1111/liv.70078
Publication Date:
2025-04-02T23:07:08Z
AUTHORS (25)
ABSTRACT
ABSTRACT Background and Aims Management of ultrasound (US)‐guided percutaneous liver biopsy (PLB) lacks standardisation. Despite the low risk major complications (< 1%), repeated blood counts up to 4 h in‐hospital observation are typically recommended. We aimed assess complication rates predictors in a large cohort patients undergoing US‐PLB across three Italian tertiary centres. included all from January 2018 December 2023. collected clinical, biochemical procedural features (needle type, insertions number, time antiplatelet/anticoagulant regimens). Safety was assessed by incidence pain complications, including vasovagal reaction, bleeding, pneumothorax, shock, hospitalisation death. Approach Results Among 1838 (mean age 55.1 years, 46.1% females, mean BMI 25.1 kg/m 2 , 74% parenchymal PLB), few were on anticoagulant/antiplatelet therapy (4.2%/16.2%); platelet count PT INR 209.7 × 10 3 /mm 1.04; 17 (0.9%) received prophylactic (blood components, thrombopoietin receptor agonists or vitamin K). Needle aspiration predominant (92%). During 5.4 ± 2.0 h, 134/1838 reported (7.4%). Major (26, 1.4%), with 14 episodes transient hypotension (0.8%); bleeding events (0.5%); 1 pneumothorax; abscess formation; haemobilia; episode chest pain. Hospitalisation rare (12, 0.7%), primarily for management. No fatalities recorded. Pain sole significant independent predictor (18/26, HR 30.6, p < 0.05), particularly when within first hour post‐procedure (15/18, 83.3%). Conclusions following strongly associated early post‐procedural In absence hour, extended monitoring may be unnecessary, allowing earlier patient discharge.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (16)
CITATIONS (1)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....